Understanding Acute Myeloid Leukemia with AML1-ETO
Molecular Mechanism of Leukemogenesis involving AML1-ETO
This research aims to uncover how a specific genetic change, called AML1-ETO, causes a type of blood cancer called Acute Myeloid Leukemia, hoping to find new ways to help patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Diego NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11074607 on NIH RePORTER |
What this research studies
Acute Myeloid Leukemia (AML) is a serious blood cancer, and a common genetic change called t(8;21) leads to a fusion protein known as AML1-ETO. While patients with this specific change often respond well to initial treatments, many experience a relapse, and options become limited. Our goal is to understand the unique molecular changes that happen in these specific AML cells. By learning more about how AML1-ETO drives the cancer, we hope to identify new weaknesses in these leukemia cells that could be targeted by future medicines.
Who could benefit from this research
Good fit: This foundational research focuses on understanding the disease mechanisms relevant to patients diagnosed with Acute Myeloid Leukemia who have the t(8;21) chromosomal translocation.
Not a fit: Patients with other types of cancer or other forms of Acute Myeloid Leukemia not involving the AML1-ETO fusion protein may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to the discovery of new treatment targets and more effective therapies for patients with t(8;21) Acute Myeloid Leukemia, especially those who experience relapse.
How similar studies have performed: This research builds upon existing knowledge of AML1-ETO in AML, aiming to uncover novel molecular details that could lead to entirely new therapeutic strategies.
Where this research is happening
La Jolla, United States
- University of California, San Diego — La Jolla, United States (Active)
Researchers
- Principal investigator: Zhang, Dong-ER — University of California, San Diego
- Study coordinator: Zhang, Dong-ER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.